Abstract: The present invention relates to the field of bacterial protein engineering and protein fibers applicable as metal-binding bionanomaterials. More specifically, the present invention relates to engineered bacterial endospore appendage (Ena) proteins modified to contain metal-binding polypeptide (MBP) inserts providing for stable, flexible and robust protein assemblies with metal-binding activity. In particular, the invention relates to methods for designing Ena-fusion proteins capable of self-assembling into fibers, and for recombinant production of said self-assembling Ena-MBP fusion protein subunits, assemblies and fibers, ensuring a sustainable source of biological material for use in metal mineralization, metal sequestration, and metal-removal applications such as waste water treatment, water softening, or bioremediation.

Abstract: Sarbecovirus binding agents, in particular antibodies and antigen-binding fragments thereof, which are capable of potently neutralizing a Sarbecovirus, in particular capable of neutralizing any one or both of SARS-COV-2, including SARS-COV-2 variants, and SARS-COV. 1. The binding agents, in particular the antibodies and antibody fragments, bind to heptad repeat 2 (HR2) domain of spike protein of the Sarbecovirus, more particularly to a quaternary epitope located within 2 adjacent HR2 domains. Also disclosed are methods using these binding agents and uses thereof.

Abstract: The present invention relates to the field of disorders of the central and peripheral nervous system, in particular neurological and psychiatric disorders, and the prevention and/or treatment thereof. In particular, the present invention relates to the finding that short peptides derived from the soluble amyloid precursor protein ? (sAPP?) bind and modulate GABABR1a. The peptides are provided for clinical use, more particularly for the treatment of neurological diseases such as CMT as well as for psychiatric disorders.

Abstract: The present invention relates to bifunctional compounds, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and/or otherwise inhibited by bifunctional compounds according to the present invention. In particular, the present invention is directed to compounds, which contain on one end a VHL ligand which binds to the ubiquitin ligase and on the other end a moiety which binds a target protein such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. The present invention exhibits a broad range of pharmacological activities associated with compounds according to the present invention, consistent with the degradation/inhibition of targeted polypeptides.

Abstract: The present invention relates to bifunctional compounds, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins that are degraded and/or otherwise inhibited by bifunctional compounds of the present invention. In particular, the present invention is directed to compounds, which contain on one end a VHL ligand that binds to the ubiquitin ligase and on the other end a moiety that binds a target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. The present invention exhibits a broad range of pharmacological activities associated with compounds of the present invention, consistent with the degradation/inhibition of targeted polypeptides.

Abstract: The present invention relates to bifunctional compounds, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and/or otherwise inhibited by bifunctional compounds according to the present invention. In particular, the present invention is directed to compounds, which contain on one end a VHL ligand which binds to the ubiquitin ligase and on the other end a moiety which binds a target protein such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. The present invention exhibits a broad range of pharmacological activities associated with compounds according to the present invention, consistent with the degradation/inhibition of targeted polypeptides.

Abstract: The present invention relates to bifunctional compounds, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins that are degraded and/or otherwise inhibited by bifunctional compounds of the present invention. In particular, the present invention is directed to compounds, which contain on one end a VHL ligand that binds to the ubiquitin ligase and on the other end a moiety that binds a target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. The present invention exhibits a broad range of pharmacological activities associated with compounds of the present invention, consistent with the degradation/inhibition of targeted polypeptides.